{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Perioperative+chemotherapy&page=2", "query": { "intervention": "Perioperative chemotherapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 56, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Perioperative+chemotherapy&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Perioperative+chemotherapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T17:47:29.466Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04048278", "title": "Lidocaine Infusion in Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Lidocaine Hydrochloride", "type": "DRUG" }, { "name": "Saline Solution for Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2018-11-08", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04048278" }, { "nct_id": "NCT03896620", "title": "Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Preoperative RT", "type": "DEVICE" }, { "name": "Postoperative RT", "type": "DEVICE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Surgery", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "DRUG", "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2019-06-18", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896620" }, { "nct_id": "NCT03579758", "title": "Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Gallbladder Cancer AJCC v8", "Stage II Gallbladder Cancer AJCC v8", "Stage IIA Gallbladder Cancer AJCC v8", "Stage IIB Gallbladder Cancer AJCC v8", "Stage III Gallbladder Cancer AJCC v8", "Stage IIIA Gallbladder Cancer AJCC v8", "Stage IIIB Gallbladder Cancer AJCC v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-04-03", "completion_date": "2020-06-01", "has_results": false, "last_update_posted_date": "2020-06-05", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 5, "location_summary": "Stanford, California • Atlanta, Georgia • New York, New York", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579758" }, { "nct_id": "NCT03982810", "title": "The Role of Guideline-adherent Perioperative Antibiotic Administration and the Risk of Surgical Site Infections After Non-cardiac Surgery.", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Surgical Site Infection", "Antibiotic Prophylaxis" ], "interventions": [ { "name": "Antibiotics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-06-01", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03982810" }, { "nct_id": "NCT05236114", "title": "GEMINI-NSCLC: NSCLC Biomarker Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2022-06-22", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05236114" }, { "nct_id": "NCT06632327", "title": "Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Resectable Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2024-12-11", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 415, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06632327" }, { "nct_id": "NCT07290985", "title": "AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Zolbetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Association for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2026-07-20", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 2, "location_summary": "Los Angeles, California • New Haven, Connecticut", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07290985" }, { "nct_id": "NCT02850874", "title": "HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Hyperthermic intraperitoneal chemotherapy", "type": "PROCEDURE" }, { "name": "Open pancreaticoduodenectomy", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2016-02", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02850874" }, { "nct_id": "NCT06465329", "title": "A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Platinum-based chemotherapy", "type": "DRUG" }, { "name": "REGN7075", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-11-18", "completion_date": "2030-05-02", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 12, "location_summary": "Orange, California • Skokie, Illinois • Detroit, Michigan + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06465329" }, { "nct_id": "NCT00667420", "title": "Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "panitumumab, epirubicin, oxaliplatin, xeloda", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2008-04", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2014-07-04", "last_synced_at": "2026-10-01T17:47:29.466Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667420" } ] }